ClinicalTrials.gg
Not yet recruitingNCT07846059REMAP-HCMUpdated Sep 29, 2026

Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Bristol-Myers Squibb · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 1 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
2nd of 15
800 · median 200
Started
2026
with 3 others
Observational
15 of 31
9 open now
Primary completion
2027-03
later than 8 of 13 live
Registered
31st of 31
by date

Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2026, is one of 15 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 31st registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

9 of the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

  • Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
  • Mavacamten
  • Hypertrophic cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include adults in China diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiated mavacamten treatment between 24 October 2024 and 31 March 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included:

  1. Diagnosis: Have a documented diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), identified by the corresponding International Classification of Diseases (ICD)-10 codes in the medical record system.
  2. Medication Exposure: Have a first-ever recorded prescription for Mavacamten within the Patient Identification Period (24 October 2024 to 31 March 2026). This date is defined as the Index Date.
  3. Age: Be ≥ 18 years of age at the Index Date.
  4. Treatment Continuity: Have at least two valid clinical records of any type (e.g., outpatient visit, inpatient encounter, prescription refill, laboratory test, or echocardiogram) after the Index Date.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Category A1. Sustained Monotherapy

    Participants who initiate mavacamten as monotherapy and remained on monotherapy throughout follow-up.

    Drug: Mavacamten

  • Category A2. Treatment Intensification

    Participants who initiate mavacamten monotherapy and subsequently added one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications during follow-up.

    Drug: Mavacamten

  • Category B1. Stable Combination Therapy at Initiation

    Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and remain on combination therapy throughout follow-up.

    Drug: Mavacamten

  • Category B2. Treatment Simplification

    Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and subsequently discontinued all background oHCM medications, resulting in mavacamten monotherapy.

    Drug: Mavacamten

  • Category C. Complex/Unclassifiable

    Participants whose treatment records indicate multiple treatment changes that could not be classified into the predefined treatment strategy groups.

    Drug: Mavacamten

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants in each study cohort

    Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15

  2. Absolute change (mmHg) from baseline in resting peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

  3. Absolute change (mmHg) from baseline in post-Valsalva peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

Secondary outcomes

  1. Number of participants with at least 1-class improvement from baseline in New York Heart Association (NYHA) functional class

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

  2. New York Heart Association (NYHA) functional class classification as assessed by the treating physician

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

  3. Change from baseline in left atrial dimension (LAD) or left atrial volume index (LAVI) assessed by transthoracic echocardiography

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

  4. Change from baseline in interventricular septal thickness (IVST) assessed by transthoracic echocardiography

    Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15

  5. Change from baseline in E/e' ratio assessed by transthoracic echocardiography

    Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15

  6. Prescribed mavacamten dose (mg)

    Time frame: Day 1 and months 1, 2, 3, 6, 9, 12 and 15

  7. Prescribed mavacamten maintenance dose (mg) during follow-up

    Time frame: Up to 15 months

  8. Number of participants reaching mavacamten maintenance dose

    Time frame: Up to 15 months

  9. Number of participants whose prescribed mavacamten dose changed during the observation period

    Time frame: Day 1 and and up to 15 months

  10. Time (days) from Index Date to achieving mavacamten maintenance dose

    Time frame: Day 1 and up to 15 months

  11. Number of participants that discontinued mavacamten treatment

    Time frame: Up to 15 months

  12. Time (days) from Index Date to mavacamten discontinuation

    Time frame: Day 1 and up to 15 months

  13. Duration of mavacamten treatment during follow-up

    Time frame: Day 1 and up to 15 months

  14. Prior hypertrophic cardiomyopathy (oHCM) medication drug class

    Drug class of background oHCM medications, including beta-blockers and calcium channel blockers

    Time frame: Baseline and up to 15 months

  15. Prior hypertrophic cardiomyopathy (oHCM) medication dose

    Dose of background oHCM medications, including beta-blockers and calcium channel blockers

    Time frame: Baseline and up to 15 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846059
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion